The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private organization funding collaborative translational science, recently launched the Adelson Program in…
News
A combination treatment including Pomalyst (pomalidomide) significantly extended the time until disease progression or death in patients with relapsed or refractory multiple myeloma who were…
PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for…
Some 68 percent of Canadians would feel helpless if they or someone close to them received a blood cancer diagnosis, found a recent poll commissioned…
Multiple myeloma patients in the United Kingdom can now potentially benefit from a new oral pill sold as Ninlaro…
In an era of new therapies with unprecedented efficacy, high-dose therapy with melphalan followed by autologous stem cell transplant (HDT/ASCT) is still associated with better progression-free…
Pretreating multiple myeloma patients with Ethyol (amifostine) prior to a stem cell transplant significantly reduces the transplant therapy’s gastrointestinal toxicity without compromising its efficacy, a…
The Multiple Myeloma Research Foundation and Karyopharm Therapeutics are hoping that 2018 will be as momentous a year as 2017 in their collaborative effort to develop…
Animal studies have shown that a new treatment strategy using phototherapy might be used to treat inaccessible cancers, including multiple myeloma. The therapy makes use…
Multiple myeloma patients who received several prior lines of therapy showed promising response rates when treated with a combination of Karyopharm Therapeutics‘Â selinexor…
